The global Glanzmann Thrombasthenia Therapeutic Drug Market growing incidences of Glanzmann thrombasthenia, especially in populations with increased consanguinity, is the primary stimulant for this market’s growth. Prompt diagnosis using platelet aggregation or flow cemetery testing and a multidisciplinary approach to treating the same will further propel market growth. Increased awareness about this unique bleeding disorder and heightened research for better prognosis will benefit market growth. The rapid development of technologically advanced healthcare facilities worldwide and the availability of more robust techniques for quantitation of platelet receptors will boost the market growth. Advancement in molecular biology techniques for accurate diagnosis of heterozygote carriers in clinically asymptomatic patients or an unborn fetus will be a market booster. Lack of awareness and skilled professionals for timely diagnosis and efficient GT management are barriers faced by this market.
The major players in the glanzmann thrombasthenia therapeutic drug market include Novo Nordisk, Alnylam Pharmaceuticals, Shire (Takeda), Biogen, Bioverativ (Sanofi), Bayer, CSL Behring, Grifols, Bristol-Myers Squibb, Pfizer.
Glanzmann Thrombasthenia Therapeutic Drug Market Segmentation
By Type
- Platelet Transfusion
- Recombinant Activated Factor VII
- Antifibrinolytics
- Fibrin Sealants
- Thrombin
- Desmopressin
- Others
By Application
- Hospital
- Clinic
- Others
The Glanzmann Thrombasthenia Therapeutic Drug market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
Source: https://www.valuemarketresearch.com/report/glanzmann-thrombasthenia-therapeutic-drug-market
Naira Shekhawat has been into Content Writing just after completing her Graduation in English Literature. Her love for words has won her many accolades in her respective jobs ever since. Naira covers business sections for VMR News. She is a traveller by heart and loves writing on food blogs as a freelancer.